Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.

This study found that the androgen precursors DHEA and androstenedione stimulated androgen-sensitive parameters in the sebaceous glands of the skin in castrated male hamsters.

This article discusses the minimal research on hair growth physiology and highlights Dr. Masumi Inaba's contributions to understanding androgenetic alopecia, but reports no new experimental results.

This commentary reviews potential dietary and mineral influences on androgenetic alopecia and suggests considering a diet low in cholesterol and glycaemic index with improved glucose control and magnesium fortification, without new clinical results.

This article discusses the role of Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants in predicting the response to oral minoxidil for treating female pattern hair loss, without presenting new research findings.

This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.

This study found that a lipid nanoemulsion-based gel of finasteride for topical use improved hair growth and was effective against alopecia, with slow skin permeation and increased efficacy compared to a testosterone-treated group.

In this study, saw palmetto supplements showed varied effects on cell growth in vitro and did not significantly inhibit growth in the hamster flank organ model despite a notable trend.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This review discusses the genetic and androgen-related factors in androgenetic alopecia, highlighting a specific polymorphism in the AR protein associated with male pattern hair loss, and reports no new clinical results.

Low-dose finasteride may cause muscle weakness and eye issues, but stopping the drug can lead to recovery.

AGA is a genetic, hormonal hair loss treated with finasteride, minoxidil, and supplements, but new compounds are being developed.

This study confirms that finasteride inhibits the conversion of testosterone to dihydrotestosterone in human dermal fibroblasts, suggesting potential therapeutic use for androgen-related skin disorders.

This review discusses the clinical implications of female androgen deficiency and evaluates treatment options, emphasizing the need for cautious use of replacement therapy in women with severe deficiency and matching symptoms.

This case report describes a 37-year-old female with non-classical congenital adrenal hyperplasia who presented with severe acne, progressive hair loss, and primary infertility, managed with prednisolone.

This study observed that both intradermotherapy with 5% minoxidil and topical minoxidil application resulted in perceived improvements in hair density and thickness among patients with androgenetic alopecia, with no significant difference between the two groups.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This study found that dihydrotestosterone alters the balance of Wnt pathway regulators in dermal papilla cells, hindering hair follicle stem cell differentiation and contributing to hair follicle miniaturization.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

In this study, researchers found no statistically significant difference in blood group distribution between patients with androgenetic alopecia and a healthy population.

The authors concluded that finasteride should be preferred over dutasteride for treating male androgenetic alopecia, as it better preserves certain important functions.

In this study, extracts of Zataria multiflora Boiss. and Matricaria chamomilla, combined with minoxidil, significantly improved hair growth in androgenetic alopecia patients by potentially inhibiting 5α-reductase activity.

In this study, elevated serum levels of aldosterone and free testosterone, along with increased androgen and aldosterone receptor levels, were associated with early-onset androgenetic alopecia in female patients.

In this study, finasteride, 1 mg daily, significantly increased hair weight more than hair count in men with androgenetic alopecia, indicating additional factors like hair growth rate and thickness may contribute to its effectiveness.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

This review discusses the potential persistent adverse effects associated with 5α reductase inhibitor treatment for androgenetic alopecia but provides no new clinical results; it emphasizes the importance of discussing these risks with patients.